Issues in Evaluating AI-Enabled Healthcare

About this session

ISSUE: As AI-enabled healthcare technologies pursue reimbursement, a fundamental methodological question confronts evaluators: how should the study population be defined? Should economic evaluation encompass all individuals with access to AI-enabled care, analogous to an intent-to-treat framework, or be restricted to those who actively engage with the technology? This distinction is consequential.

Speakers

• SK

  Seamus Kent

  Erasmus University Rotterdam

  Moderator

• AC

  Anastasia Chalkidou

  NICE

  Panelist

• BA

  Blythe Adamson

  Doctronic

  Panelist

• LB

  Lena Bertozzi

  Pomelo Care

  Panelist